| Study Protocol Number | Study Title and Description |
|---|---|
| 24-2380 |
1186372COR3002 - OrigAMI-3: A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI VersusCetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus either cetuximab or bevacizumab and FOLFIRI given ... |
| 25-0217 |
A Phase 1 Study of Peposertib (M3814) and Low-Dose Liposomal Doxorubicin in Patients with Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas
Dose Escalation: To evaluate the safety and tolerability of peposertib in combination with low-dose liposomal doxorubicin as evaluated by the dose-limiting toxicity (DLT) rate at each tested dose level. Dose Escalation: To determine the recommended phase 2 dose (RP2D) of liposomal doxorubicin and peposertib combination and determine the maximal tolerated dose (MTD) if identified. Dose Expansion:... |
| 24-0118 |
A phase II Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients with Advanced or Metastatic Soft Tissue Sarcomas
Determine the efficacy of treatment with weekly doxorubicin chemotherapy in anthracycline-naïve elderly patients with advanced or metastatic LMS of soft tissue. |
| 25-1233 |
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects with Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study
A first in human study to evaluate the safety and preliminary antitumor activity of BBO-8520, a KRAS G12C (ON and OFF) inhibitor, as a single agent and in combination with pembrolizumab in subjects with locally advanced and unresectable or metastatic non-small cell lung cancer with a KRAS (Kirsten rat sarcoma) G12C mutation. |
| 24-2281 |
A First-in-human, Phase 1/2, Multicenter, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor activity of ADCE-D01, a Humanized Anti-human uPARAP Antibody Linked to a Topoisomerase I Inhibitor, in Patients with Metastatic and/or Unresectable Soft Tissue Sarcoma
-To determine the MTD/maximum administered dose and RP2DS of ADCE-D01. -To assess the safety and tolerability of ADCE-D01. |
| 25-2548 | |
| 25-2381 |
An Open-label, Multicenter Study of DPTX3186 to Evaluate Safety, Tolerability, and Pharmacokinetics in Subjects with Known Wnt-Pathway Activated Solid Tumors Where No Other Treatments Exist
This is a first-in human clinical study of DPTX3186 in subjects with Wnt-pathway activated solid tumors where no other treatments exist. The study will evaluate safety, pharmacokinetics, and initial activity of DPTX3186, as well as explore pharmacodynamic parameters to identify potential biomarkers of efficacy |
| 25-2227 |
A Study of FOG-001 for People with Advanced Cancer
The purpose of this study is to learn about the safety of FOG-001, find the best dose, and see how it affects the body. Researchers will also study how well it works in treating advanced or metastatic cancer when used alone or with other cancer treatments. |
| 25-0466 |
Combining Ziftomenib and Imatinib to Treat Advanced Gastrointestinal Stromal Tumors
This study wants to find a dose of ziftomenib that people with advanced gastrointestinal stromal tumors (CIST) can handle safely when taken with imatinib. We also want to learn how well these two drugs work together. |
| 24-2282 |
A Master Protocol for the Multi-cohort, Open-label, Phase 1/2 Study of DCC-3009 in Participants With Gastrointestinal Stromal Tumors (GIST)
• To evaluate the safety and tolerability of DCC-3009 as monotherapy in participants with advanced GIST. • To determine the recommended dose(s) for expansion in Module A, and if reached, the maximum tolerated dose (MTD) of DCC-3009 as monotherapy. |
| 23-2048 |
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors.
This study is open to adults with different types of advanced cancer (solid tumors) that are accessible for injection and/or biopsy. This is a study for people with a life expectancy of at least 3 months after starting study treatment. The purpose of this study is to find the highest dose of a medicine called BI 1831169 that people with advanced cancer can tolerate when taken with or without a typ... |
| 18-2740 |
Study on the Safety and Effectiveness of a New Oral Drug Combination Therapy to Treat Bone Cancer in Children and Adults
This study wants to find a new combination of drugs that is safe and effective to treat people who have bone cancer that has come back or not responded to other treatments. |
| 15-1110 |
Total Cancer Care Protocol: A Lifetime Partnership with Patients Who Have or May be at Risk of Having Cancer (ORIEN)
The overall objective of this study is to ultimately develop an improved standard of cancer care by facilitating new clinical trials, new technology, new informatics solutions and "personalized medicine". |